🟢 Lantern Pharma is trading 5.3% up today on EMA clearance for bladder cancer trial

Lantern Pharma is trading 5.3% up today at $2.77 as investor momentum builds following a major regulatory milestone in Europe.

• The European Medicines Agency (EMA) has cleared a Phase 1b/2 clinical trial for the company's lead drug candidate, LP-184, specifically targeting bladder cancer.
• The stock is extending a multi-day rebound from last week's lows, fueled by positive sentiment surrounding the progress of its oncology pipeline.
• This regulatory clearance is considered a significant step forward in the clinical development and potential commercialization of LP-184.